



CE ISO 13485 : 2016

# AMKAY PRODUCTS LIMITED

## Mfg.of Medical Devices & Disposables

Regd. Office : Amkay Enclave, 68, Rashmi Park Bungalow, Dhumaal Nagar, Waliv Road, Vasai (East), Palghar - 401208, Maharashtra, India.

Email : info@amkayproducts.com Website : www.amkayproducts.com

Phone : 91520 94440 CIN : U51397MH2007PLC175403

Date: 29<sup>th</sup> May, 2024

To,  
The Manager Compliance  
Department BSE Limited  
P.J. Towers, Dalal Street,  
Fort Mumbai-400001

Scrip Code: 544169

### **Sub.: Outcome of Board Meeting held on 29<sup>th</sup> May, 2024**

Pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 and other applicable provisions, if any, We would like to inform you that the meeting of the Board of Directors of Amkay Products Limited held today i.e. Wednesday, 29<sup>th</sup> May, 2024 through VC/OAVM inter-alia has considered and approved the following businesses:

1. Audited financial results for the quarter and year ended March 31, 2024 of the company along with Audit Report are enclosed herewith for information and record;
2. Appointment of M/s. Pimple & Associates as a Secretarial Auditor for the F.Y. 2024-25;
3. To Invest additional fund in Mutual Fund / Fixed Deposit as avail OD facility as and when required;
4. To Dispose the amount Invested in Mutual Fund;
5. Appointment of M/s. Soni Punit & Associates as an Internal Auditor of the Company for the F.Y. 2024-25;

Please note that in terms of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the securities of the Company will open after 48 hours of the results are made public on Wednesday, 29<sup>th</sup> May, 2024.

Also please note that the Board meeting commenced at 4.00 p.m. to conclude at 5.12 p.m.

Kindly take the same on your record.

*Your Partner in Healthcare*





CE ISO 13485 : 2016

# AMKAY PRODUCTS LIMITED

## Mfg.of Medical Devices & Disposables

**Regd. Office :** Amkay Enclave, 68, Rashmi Park Bungalow, Dhumaal Nagar, Waliv Road, Vasai (East), Palghar - 401208, Maharashtra, India.

**Email :** info@amkayproducts.com **Website :** www.amkayproducts.com

**Phone :** 91520 94440 **CIN :** U51397MH2007PLC175403

Thanking You

Yours Faithfully

**For Amkay Products Limited**

---

**Kashyap Pravin Mody**  
**Managing Director**  
**DIN: 01717036**

*Your Partner in Healthcare*





**Amkay Products Limited**

Registered Office - : Bunglow No.68,Rashmi Park Chs Ltd, Dhumal Nagar Wallv Road, Tal-Vasal Dist- Thane Vasal Thane Maharashtra - 401208 ,  
CIN - : U51397MH2007PLC175403

**Profit & Loss Statement For The Half Year Ended & Year Ended March 31st, 2024**

(Rs In Lakhs)

Sr. No.	Particulars	Half Year Ended		Year ended	
		31-Mar-24	30-Sep-23	31-Mar-24	31-Mar-23
	<b>Whether Results are Audited or Unaudited</b>	<b>Audited</b>	<b>Unaudited</b>	<b>Audited</b>	<b>Audited</b>
I	Revenue From Operations	1669.45	1437.46	3106.91	2786.42
II	Other Income	78.46	48.46	124.92	46.47
III	<b>Total Revenue (I+II)</b>	<b>1745.90</b>	<b>1485.93</b>	<b>3231.83</b>	<b>2832.89</b>
IV	<b>Expenses:</b>				
a	Cost Of Material Consumed	933.90	793.29	1727.19	1237.28
b	Purchase Of Stock-In-Trade	327.15	209.84	536.99	844.01
c	Changes In Inventories Of Finished Goods, Work-In-Progress And Stock - In-Trade	32.02	-83.79	-51.77	-37.41
d	Employee Benefits Expenses	132.71	107.90	240.61	197.53
e	Finance Costs	28.33	23.89	52.22	47.01
f	Depreciation And Amortization Expense	29.51	26.09	55.60	69.12
g	Other Expenses	89.53	231.37	320.69	252.12
	<b>Total Expenses</b>	<b>1573.15</b>	<b>1308.58</b>	<b>2881.73</b>	<b>2609.66</b>
V	<b>Profit Before Exceptional And Extraordinary Items And Tax (III-IV)</b>	<b>172.75</b>	<b>177.34</b>	<b>350.10</b>	<b>223.23</b>
VI	Exceptional Items				
VII	<b>Profit Before Extraordinary Items And Tax (V-VI)</b>	<b>172.75</b>	<b>177.34</b>	<b>350.10</b>	<b>223.23</b>
VIII	Extraordinary Items				
IX	<b>Profit Before Tax (VII-VIII)</b>	<b>172.75</b>	<b>177.34</b>	<b>350.10</b>	<b>223.23</b>
X	<b>Tax Expense</b>				
	Current Tax	34.60	42.32	76.91	56.25
	Earliar Years Tax	4.99	-1.24	3.75	47.03
	Deferred Tax	-0.24	-6.19	-6.44	34.94
XI	<b>Profit(Loss) For The Period From Continuing Operations (IX-X)</b>	<b>132.93</b>	<b>130.07</b>	<b>263.00</b>	<b>154.89</b>
XII	Profit (Loss) From Discontinuing Operations	0.00	0.00	0.00	0.00
XIII	Tax Expense Of Discontinuing Operations	0.00	0.00	0.00	0.00
XIV	<b>Profit(Loss) From Discontinuing Operations After Tax (XII-XIII)</b>	<b>132.93</b>	<b>130.07</b>	<b>263.00</b>	<b>154.89</b>
XV	<b>Profit (Loss) For The Period</b>	<b>132.93</b>	<b>130.07</b>	<b>263.00</b>	<b>154.89</b>
XVI	<b>Earning Per Equity Share (Face Value of Rs . 10/-)</b>				
	Basic	2.09	2.04	4.13	2.43
	Diluted	2.09	2.04	4.13	2.43

**Notes on Financial Result:-**

- The above result have been reviewed by the Audit Committee and have been approved by the Board of Directors of the company at their respective meetings hold on 29th May, 2024.
  - The results for the half year and year ended 31st March, 2024 has been Audited by the statutory auditor of the company in compliance with regulation 33 of SEBI(listing obligations and disclosure requirements) regulation, 2015.
  - The figure for the half year ended March 31 2024, as reported in these financial results are the balancing figures between audited figures in respect of full financial year and the Unaudited figures for the period April 1, 2023 to September 30, 2023 as certified by the management.
- As per Accounting standard 17 on "segment Reporting" (AS-17), the company has only one reportable segment viz Healthcare Devices and 4 consumable and product, therefore segment disclosure is not applicable.
- As per MCA notification dated 16th February, 2015 Companies whose shares are listed on SME exchange as referred to chapter IX of SEBI (Issue of 5 Capital and Disclosure Requirements) Regulation 2018 are exepmpted from compulsory requirement of adoption of IND-AS.
- 6 Earning Per Share are calculated on weighted avergae of the Share Capital Outstanding during the year/half year/ period EPS is not annualised.
- This company was listed on BSE on 8th May, 2024, therefore Comparable Statement of Profit and Loss for the 2nd half of immediately preceding year 7 ended Mar'23 is not available, and accordingly not reported.
- 8 Previous year's/ period's figure have been regrouped/rearmaged wherever necessary.

For And On Behalf Of Board,  
Amkay Products Limited

Kashyap Pravin Mody  
DIN: 01717036  
Managing Director & Chairman



Date:-29th May 2024  
Place:- Mumbai



**Amkay Products Limited**

Registered Office - : Bunglow No.68,Rashmi Park Chs Ltd, Dhumal Nagar Waliv Road, Tal-Vasai Dist- Thane Vasai Thane Maharashtra - 401208 , CIN - : U51397MH2007PLC175403

**BALANCE SHEET AS AT 31ST MARCH, 2024**

(Rs In Lakhs)

Sr. No.	Particulars	Note No.	AS AT	
			31-Mar-24	31-Mar-23
<b>I</b>	<b>Equity And Liabilities</b>		<b>Audited</b>	<b>Audited</b>
<b>1</b>	<b>Shareholders Funds</b>			
a	Share Capital	1	636.36	27.67
b	Reserves And Surplus	2	363.80	709.50
	<b>Total (1)</b>		<b>1000.17</b>	<b>737.17</b>
<b>2</b>	<b>Share Application Money Pending Allotment</b>			
	<b>Total (2)</b>		<b>0.00</b>	<b>0.00</b>
<b>3</b>	<b>Non-Current Liabilities</b>			
a	Long Term Borrowings	3	127.51	334.99
b	Deferred Tax Liabilities (Net)		0.00	0.00
c	Other Long-Term Liabilities			
d	Long-Term Provisions		7.09	5.20
	<b>Total (3)</b>		<b>134.61</b>	<b>340.19</b>
<b>4</b>	<b>Current Liabilities</b>			
a	Short-Term Borrowings	4	418.65	134.99
b	Trade Payables	5		
	(i) total outstanding dues of micro enterprises and small enterprises; and		166.16	0.00
	(ii) total outstanding dues of creditors other than micro enterprises and small enterprises.		40.15	249.27
c	Other Current Liabilities	6	34.09	27.04
d	Short Term Provisions	7	1.05	10.06
	<b>Total (4)</b>		<b>660.09</b>	<b>421.37</b>
	<b>Total Equity &amp; Liabilities (1+2+3+4)</b>		<b>1794.86</b>	<b>1498.72</b>
<b>II</b>	<b>Assets</b>			
<b>1</b>	<b>Non-Current Assets</b>			
a	Property Plant & Equipment & Intangible Assets	8	257.91	240.49
	(i) Property Plant & Equipment		257.46	240.49
	(ii) Intangible Assets		0.44	0.00
b	Non-Current Investments	9	256.71	323.11
c	Deferred Tax Assets (Net)	9A	21.33	27.76
d	Long-Term Loans And Advances	10	44.76	29.09
e	Other Non-Current Assets	11	0.00	0.00
	<b>Total (1)</b>		<b>580.70</b>	<b>620.46</b>
<b>2</b>	<b>Current Assets</b>			
a	Current Investment	12	66.68	38.81
b	Inventories	13	561.39	260.82
c	Trade Receivables	14	398.85	370.49
d	Cash And Cash Equivalents	15	10.81	4.99
e	Short-Term Loans And Advances	16	149.45	196.52
f	Other Current Assets	17	26.98	6.63
	<b>Total (2)</b>		<b>1214.16</b>	<b>878.25</b>
	<b>Total Assets (1+2)</b>		<b>1794.86</b>	<b>1498.72</b>

For And On Behalf Of Board  
Amkay Products Limited



Kashyap P. Medy  
Managing Director & Chairman  
DIN No : 01717036

Date: 29th May 2024  
Place: Mumbai



**STATEMENT OF CASH FLOW FOR THE YEAR ENDED MARCH 31, 2024**

(Amount in ₹ Lakhs)

Particulars	For the year ended March 31, 2024 (Audited)	For the year ended March 31, 2023 (Audited)
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>		
Net profit before tax	350.10	223.23
Adjustments for:		
Depreciation and amortisation expense	55.60	69.12
(Profit) / Loss on sale of fixed assets	0.00	-3.71
(Profit) / Loss on Sale of investments	-94.32	-30.19
Interest and other income on investments	-3.18	-10.55
Interest expenses	47.35	22.44
Provision for Gratuity	1.95	5.52
	<b>357.49</b>	<b>275.85</b>
Operating profit / (loss) before working capital changes		
<b>Changes in working capital:</b>		
Increase / (Decrease) in trade payable	-42.97	-205.37
Increase / (Decrease) in other current liabilities	7.00	12.66
Increase / (Decrease) in Short term provisions	-9.01	10.06
(Increase) / Decrease in inventories	-300.58	-62.41
(Increase) / Decrease in trade receivables	-28.35	-7.02
(Increase) / Decrease in short term loan and advances	56.08	76.92
(Increase) / Decrease in Other Current Assets	-20.35	-6.05
	<b>-338.18</b>	<b>-181.21</b>
<b>CASH FLOW FROM / (USED IN) OPERATING ACTIVITIES</b>	<b>19.31</b>	<b>94.65</b>
Less: Income Taxes paid	-89.67	-93.23
<b>NET CASH FLOW FROM / (USED IN) OPERATING ACTIVITIES</b>	<b>-70.37</b>	<b>1.42</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>		
Purchase of tangible / intangible assets net of Subsidy Received	-73.01	-2.34
(Increase) / Decrease in long term loan and advances	-15.67	18.16
(Increase) / Decrease in non current Assets	0.00	0.00
(Profit)/Loss on sale of investments	94.32	30.19
Investment in fixed deposits	-27.87	16.75
Investment in Mutual Fund	66.40	-107.11
Income from Interest	3.18	10.55
<b>NET CASH FLOW FROM / (USED IN) INVESTING ACTIVITIES</b>	<b>47.36</b>	<b>-33.79</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>		
Proceeds from Issue of Share Capital	0.00	0.00
Interest expenses	-47.35	-22.44
Increase/(Decrease) in Short-term Borrowing	283.65	65.63
Increase/(Decrease) in Long-term Borrowing	-207.48	-12.01
Increase/(Decrease) in Other Long Term Liabilities	0.00	0.00
<b>NET CASH FLOW FROM / (USED IN) FINANCING ACTIVITIES</b>	<b>28.82</b>	<b>31.18</b>
<b>NET INCREASE / (DECREASE) IN CASH &amp; CASH EQUIVALENTS (A+B+C)</b>	<b>5.82</b>	<b>-1.19</b>
Cash and Cash equivalents at beginning period <sup>1</sup> (Refer Note 14)	4.99	6.18
Cash and Cash equivalents at end of period (Refer Note 14)	<b>10.81</b>	<b>4.99</b>
<b>D. Cash and Cash equivalents comprise of</b>		
Cash on hand	4.20	3.08
<u>Balances with banks</u>		
In current accounts	6.60	1.91
Other Balances	0.00	0.00
<b>Total</b>	<b>10.81</b>	<b>4.99</b>

This Cash Flow Statement has been prepared as per "Indirect Method" as prescribed by Accounting Standard -3 (revised)  
"Cash Flow Statements"

For and on behalf of the Board of  
Amkay Product Limited



Kashyap Pravin Mody  
DIN: 01717030  
Managing Director & Chairman



Date: 29th May 2024  
Place: Mumbai



---

**INDEPENDENT AUDITOR'S REPORT ON THE HALF YEARLY AND YEAR TO DATE  
AUDITED FINANCIAL RESULTS OF THE COMPANY**

**TO THE BOARD OF DIRECTORS OF  
AMKAY PRODUCT LIMITED**

**Opinion**

We have audited the accompanying statement of half yearly and year to date financial results of **AMKAY PRODUCT LIMITED** ("the company") for the half year and year ended March 31, 2024 ("Statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the statement:

- a. is presented in accordance with the requirements of the Listing Regulations in this regard; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Accounting Standards and other accounting principles generally accepted in India of the net profit and other financial information for the half year and year ended March 31, 2024.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statement under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained by us is sufficient and appropriate to provide a basis for our opinion.

**Managements and Board of Directors' Responsibilities for the Annual Financial Results**

These annual financial results have been prepared on the basis of the annual financial statements. The Company's Management and Board of Directors are responsible for the preparation of these annual financial results that give a true and fair view of the net profit and other financial information in accordance with the recognition and measurement principles laid down in Accounting Standard prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the annual financial results, the Management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Annual Financial Results**

Our objectives are to obtain reasonable assurance about whether the annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, Under Section 143(3) (i) of the Companies Act 2013, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the annual financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and

other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**Other Matters**

The annual financial results include the results for the half year ended March 31, 2024, being the balancing figure between audited figures in respect of the full financial year and the published unaudited year to date figure up to the six months ended September 30, 2023, of the current financial year which is certified by management.

Our opinion on the annual financial results is not modified in respect of this matter.

**For R K Jagetiya & Co**  
Chartered Accountants  
FRN 146264W

RAVI  
KANT  
JAGETIYA

Digitally signed by RAVI KANT JAGETIYA  
DN: cn=R, o=PERSONAL,  
postalCode=400055, st=24, serial=91677  
4193026,  
c=IN, email=214.204.40.29.1711456.40030  
b642980481184da98219901a4025ac2  
c, serial=400055, o=PERSONAL, email=916774  
serialNumber=73a23a1b-2448-10811472  
e07018437912a33890712578485051  
c04412, cn=RAVI KANT JAGETIYA  
Date: 2024.05.29 17:14:56 +05'30'

**(Ravi K Jagetiya)**  
Proprietor  
Membership No. 134691  
Date: 29<sup>th</sup> May, 2024  
Place: Mumbai  
UDIN: **24134691BKADCT3751**





CE ISO 13485 : 2016

# AMKAY PRODUCTS LIMITED

## Mfg.of Medical Devices & Disposables

Regd. Office : Amkay Enclave, 68, Rashmi Park Bungalow, Dhumaal Nagar, Waliv Road, Vasai (East), Palghar - 401208, Maharashtra, India.

Email : info@amkayproducts.com Website : www.amkayproducts.com

Phone : 91520 94440 CIN : U51397MH2007PLC175403

Date: 29<sup>th</sup> May, 2024

To,  
The Manager Listing  
Department BSE Limited  
P.J. Towers, Dalal Street,  
Fort, Mumbai-400001

Scrip Code: **544169**

**Sub.: Declaration pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir/Madam,

Pursuant to the provision of Regulation 33 (3) (d) of SEBI (Listing obligations an Disclosure Requirements) Regulations, 2015 as amended by SEBI Notification No. SEBI/LAD-NRO/GN/2016-17/001 dated May 25, 2016 read with SEBI Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016; we hereby declared that the Statutory Auditors of the Company M/s. R K Jagetiya & Co., Chartered Accountants, Mumbai (Firm Registration No. 146264W) have issued the Audit Reports with Unmodified Opinion in respect of the Audited Financial Results for the quarter & year ended on March 31, 2024.

Kindly take the same on your record.

Thanking you,

Yours faithfully,

**For Amkay Products Limited**

**Kashyap Pravin Mody**  
**Managing Director**  
**DIN: 01717036**

*Your Partner in Healthcare*

